+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global HDAC (histone deacetylase) Inhibitors Market 2019-2023 - Product Image

Global HDAC (histone deacetylase) Inhibitors Market 2019-2023

  • ID: 4764931
  • Report
  • Region: Global
  • 117 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • CELGENE CORPORATION
  • Merck & Co., Inc.
  • Novartis AG
  • MORE
The development of novel drug delivery systems and combination therapies will drive the HDAC inhibitors market growth during the forecast period. Chemotherapeutic drugs are increasingly being administered orally or intravenously for treating different tumors. However, there are instances that these active pharmaceutical ingredients often do not reach the targeted site in appropriate quantities, eventually, lowering the performance of the drugs. As a result, with the rising shift of research and prescription toward combination therapies using HDAC inhibitors, the market is expected to witness considerable growth during the forthcoming years. The analysts have predicted that the HDAC (histone deacetylase) inhibitors market will register a CAGR of nearly 7% by 2023.

Market Overview

High prevalence of oncology indications

One of the growth drivers of the global HDAC (histone deacetylase) inhibitors market is the high prevalence of oncology indications. The high growth in various types of cancers and neurologic conditions, coupled with high unmet need in the treatment landscape of these diseases will drive the growth of the market.

High costs associated with treatment

One of the challenges in the growth of the global HDAC (histone deacetylase) inhibitors market is the high costs associated with treatment. The high treatment costs act as a barrier for drug adoption, which reduces the patient base and poses a challenge to market growth.

For the detailed list of factors that will drive and challenge the growth of the HDAC (histone deacetylase) inhibitors market during 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Companies are focusing on research on several other types of cancers using HDAC inhibitors due to their high target affinity and specificity. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CELGENE CORPORATION
  • Merck & Co., Inc.
  • Novartis AG
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY ROA
  • Market segmentation by RoA
  • Comparison by RoA
  • Oral HDAC inhibitors - Market size and forecast 2018-2023
  • Parenteral HDAC inhibitors - Market size and forecast 2018-2023
  • Market opportunity by RoA
PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CELGENE CORPORATION
  • Merck & Co., Inc.
  • Novartis AG
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Spectrum Pharmaceuticals, Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Customer landscape
Exhibit 18: RoA - Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Oral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral HDAC inhibitors: Pipeline overview
Exhibit 22: Oral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Prevalence of top 5 cancers newly reported in US 2015
Exhibit 43: Pipeline of combination therapies - Syndax
Exhibit 44: Treatment costs of HDAC inhibitors
Exhibit 45: Alternative treatment options for oncology conditions
Exhibit 46: Side effects of HDAC
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Some strategic alliances in global HDAC inhibitors market
Exhibit 49: drugs with respect to their cancer indications and expanded indications
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: CELGENE CORPORATION - Vendor overview
Exhibit 56: CELGENE CORPORATION - Business segments
Exhibit 57: CELGENE CORPORATION - Organizational developments
Exhibit 58: CELGENE CORPORATION - Geographic focus
Exhibit 59: CELGENE CORPORATION - Key offerings
Exhibit 60: CELGENE CORPORATION - Key customers
Exhibit 61: Merck & Co., Inc. - Vendor overview
Exhibit 62: Merck & Co., Inc. - Business segments
Exhibit 63: Merck & Co., Inc. - Organizational developments
Exhibit 64: Merck & Co., Inc. - Geographic focus
Exhibit 65: Merck & Co., Inc. - Segment focus
Exhibit 66: Merck & Co., Inc. - Key offerings
Exhibit 67: Merck & Co., Inc. - Key customers
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Novartis AG - Key customers
Exhibit 75: Shenzhen Chipscreen Biosciences Co., Ltd. - Vendor overview
Exhibit 76: Shenzhen Chipscreen Biosciences Co., Ltd. - Organizational developments
Exhibit 77: Shenzhen Chipscreen Biosciences Co., Ltd. - Key offerings
Exhibit 78: Shenzhen Chipscreen Biosciences Co., Ltd. - Key customers
Exhibit 79: Spectrum Pharmaceuticals, Inc. - Vendor overview
Exhibit 80: Spectrum Pharmaceuticals, Inc. - Business segments
Exhibit 81: Spectrum Pharmaceuticals, Inc. - Organizational developments
Exhibit 82: Spectrum Pharmaceuticals, Inc. - Geographic focus
Exhibit 83: Spectrum Pharmaceuticals, Inc. - Key offerings
Exhibit 84: Spectrum Pharmaceuticals, Inc. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • CELGENE CORPORATION
  • Merck & Co., Inc.
  • Novartis AG
  • MORE
Global HDAC (Histone Deacetylase) Inhibitors Market 2019-2023

The analyst recognizes the following companies as the key players in the global HDAC (histone deacetylase) inhibitors market: CELGENE CORPORATION, Merck & Co., Inc., Novartis AG, Shenzhen Chipscreen Biosciences Co., Ltd., and Spectrum Pharmaceuticals, Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness about cancer.”

According to the report, one of the major drivers for this market is the development of novel drug delivery systems and combination therapies.

Further, the report states that one of the major factors hindering the growth of this market is the high costs associated with treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • CELGENE CORPORATION
  • Merck & Co., Inc.
  • Novartis AG
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Spectrum Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll